ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 816

Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials

Dafna D. Gladman1, Philip J. Mease2, Arthur Kavanaugh3, Adewale O. Adebajo4, Juan J. Gomez-Reino5, Jürgen Wollenhaupt6, Maurizio Cutolo7, Georg Schett8, Eric Lespessailles9, Kamal Shah10, ChiaChi Hu10, Randall M. Stevens10, Christopher J. Edwards11 and Charles A. Birbara12, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 3University of California San Diego, San Diego, CA, 4Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, 5Hospital Clinico Universitario, Santiago, Spain, 6Schön Klinik Hamburg-Eilbek, Hamburg, Germany, 7University of Genova, Genova, Italy, 8Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 9University of Orléans, Orléans, France, 10Celgene Corporation, Warren, NJ, 11University of Southampton, Southampton, United Kingdom, 12University of Massachusetts Medical School, Worcester, MA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Psoriatic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the efficacy and safety of APR with placebo (PBO) in pts with active PsA despite prior DMARDs and/or biologics.

Methods: Pts were randomized 1:1:1 to PBO, APR 20 mg BID (APR20), or APR 30 mg BID (APR30) stratified by baseline DMARD use. At wk 16, pts with <20% reduction from baseline in swollen and tender joint counts qualified for protocol-defined early escape; those on PBO were re-randomized to APR20 or APR30 and those on APR remained on the initial APR dose. At wk 24, all remaining PBO pts were re-randomized to APR20 or APR30 through wk 52. Pts taking concurrent DMARDs were allowed to continue stable doses (MTX, sulfasalazine, leflunomide, or a combination). In order to increase the number of pts with pre-existing enthesopathy and/or dactylitis, data were pooled across PALACE 1, 2, and 3. Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), ranging from 0-13, is the number of painful entheses out of 13 entheses. The dactylitis count, ranging from 0-20, is the number of digits on the hands and feet with dactylitis present; each digit is rated as 0 (no dactylitis) or 1 (dactylitis present).

Results: APR administration resulted in statistically significant and clinically meaningful improvement in ACR20 response (primary endpoint) in all 3 PALACE trials. In pts originally randomized to APR and with pre-existing enthesopathy (n=634) and/or dactylitis (n=428), APR was associated with improvements in the severity of enthesitis and dactylitis over the 52-wk period, as evidenced by reductions in MASES and dactylitis count. At wk 24, median changes in MASES were -21.1%, -40.0% (P=0.0789), and -50.0% (P=0.0167) in pts receiving PBO, APR20, and APR30, respectively. In those pts originally randomized to APR and completing 52 wks of study, median change in MASES was -66.7% with APR20 and APR30 (Table). A MASES score of 0, indicating no pain at any of the entheses assessed, was achieved by 41.4% of APR20 and 37.4% of APR30 pts. At wk 24, median changes in dactylitis count were -66.7%, -75.0% (P=0.2158), and -79.3% (P=0.0609) in pts receiving PBO, APR20, and APR30, respectively. At wk 52, both doses resulted in a median 100% decrease in dactylitis count. Dactylitis count decreased to 0 in 66.9% of APR20 and 65.9% of APR30 pts. Pts randomized to APR at wks 16 and 24 demonstrated results consistent with those originally randomized to APR. No new safety findings were identified and the incidence of pts experiencing any AE was comparable over the 0-24 and 0-52 wk periods.

Conclusion: Over 52 wks, APR continued to demonstrate efficacy in the treatment of PsA, including improvements in enthesitis and dactylitis. APR demonstrated an acceptable safety profile and was generally well tolerated for up to 52 wks.


Disclosure:

D. D. Gladman,

Janssen, Abbvie, Amgen, Pfizer, UCB, Novartis, Lily, Celgene,

2,

Janssen, Abbvie, Amgen, Pfizer, UCB, Novartis, Lily, Celgene,

5;

P. J. Mease,

Celgene,

2,

Merck Pharmaceuticals,

2,

Novartis Pharmaceutical Corporation,

2,

Abbvie,

2,

Amgen,

2,

BiogenIdec,

2,

BMS,

2,

Genentech and Biogen IDEC Inc.,

2,

Janssen Pharmaceutica Product, L.P.,

2,

Eli Lilly and Company,

2,

Pfizer Inc,

2,

UCB,

2,

Celgene,

5,

Merck Pharmaceuticals,

5,

Novartis Pharmaceutical Corporation,

5,

Abbvie,

5,

Amgen,

5,

BiogenIdec,

5,

BMS,

5,

Genentech and Biogen IDEC Inc.,

5,

Janssen Pharmaceutica Product, L.P.,

5,

Eli Lilly and Company,

5,

Pfizer Inc,

5,

UCB,

5,

Abbvie,

8,

Amgne,

8,

BiogenIdec,

8,

BMS,

8,

Genentech and Biogen IDEC Inc.,

8,

Janssen Pharmaceutica Product, L.P.,

8,

Eli Lilly and Company,

8,

Pfizer Inc,

8,

UCB,

8;

A. Kavanaugh,

AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB,

2,

AbbVie Inc., Amgen, Astra-Zeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB,

5;

A. O. Adebajo,
None;

J. J. Gomez-Reino,

BMS, Pfizer, Roche, Schering-Plough, and UCB SA,

5,

BMS, Roche, Schering-Plough, and Wyeth,

8,

Roche and Schering-Plough,

2;

J. Wollenhaupt,

Abbott Laboratories, Bristol-Myers Squibb, MSD, Pfizer, and UCB,

5;

M. Cutolo,

BMS, Sanofi and Actelion,

2;

G. Schett,

Celgene,

2,

Abbott Laboratories, UCB, Roche,

5;

E. Lespessailles,

Novartis, Lilly, Servier, Amgen,

2,

Novartis, Lilly,

8;

K. Shah,

Celgene Corporation,

3;

C. Hu,

Celgene Corporation,

3;

R. M. Stevens,

Celgene Corporation,

3;

C. J. Edwards,

Pfizer,

2,

Pfizer, Samsung, Roche, Celgene,

5,

Roche, Pfizer, Abbott, Glaxo-SmithKline,

8;

C. A. Birbara,

Amgen, Lilly, Pfizer, Incyte, Merck, Bristol-Myers Squibb,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/apremilast-an-oral-phosphodiesterase-4-inhibitor-is-associated-with-long-term-52-week-improvements-in-enthesitis-and-dactylitis-in-patients-with-psoriatic-arthritis-pooled-results-from-three-phas/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology